Methods and matrices: approaches to identifying miRNAs for Nasopharyngeal carcinoma

Table 2 Shows the serum samples for this study consists of anonymously coded vials of sera from histopathologically confirmed cases of nasopharyngeal carcinoma (NPC) and their corresponding healthy controls from studies undertaken by the National Cancer Institute, National Institutes of health, USA and detailed in manuscripts 30, 31, 32, and 40

Origin¹	Sample	Sex			Age	WHO [40] classification	Subtype	Ethnicity	Ref
Origin¹	Sample	N	M	F	Mean (95% CI)	WHO [40] classification	Subtype	Ethnicity	Ref
Germany⁴	Case²	10	10	0	60.5 (50.7, 70.3)	Non-keratinizing	Differentiated	Caucasian	[31]
Germany⁴	Control	6	5	1	NA³	Healthy		Caucasian	[31]
USA⁵	Case	5	3	2	60.0 (48.9, 71.2)	Non-keratinizing	Differentiated	Caucasian	[32]
USA⁵	Control	3	2	1	61.0 (41.2, 80.8)	Healthy		Caucasian	[32]
Malaysia⁶	Case	12	12	0	49.5 (44.9, 54.1)	Non-keratinizing	Undifferentiated	Asian	[29, 41]
Malaysia⁶	Control	4	4	0	50.0 (39.6, 60.4)	Healthy		Asian	[29, 41]
Total	Case	27	25	2	52.1 (47.8, 56.3)	--	--	--	--
Total	Control	13	11	2	53.7 (43.8, 64.1)	--	--	--	--

The samples were maintained under Good Biobanking Practices at the Biorepositories and Biospecimen Research Branch (BBRB), National Cancer Institute, Frederick, MD, National Institutes of Health, USA.
¹All specimens biobanked and received from the Biorepositories and Biospecimen Research Branch (BBRB), National Cancer Institute, National Institute of Health, USA.
²The term “case” refers to histologically confirmed nasopharyngeal carcinoma.
³NA indicates an absence of data for this group.
⁴Ear Nose and Throat Clinic, Cologne University, Germany.
⁵North American NPC Study, Mayo Clinic, USA.
⁶Institute of Radiotherapy, Oncology and Nuclear Medicine at the General Hospital, Kuala Lumpur, Malaysia.

ISSN: 1479-5876